May. 20 at 8:01 AM
$TLSA good interview released with Ivor. I think Foralumab is looking really quite derisked at the moment and the phase 2a results would appear very likely to be very impressive. This is reflected in the broker price upgrade where they included an almost 50% rate of success in their calculations.
Foralumab just clearly works, is better than anything else out there and has literally zero safety concerns, driven by it being a fully human antibody and the fact that it is introduced nasally, rather than intravenous.
It’s also worth noting that the
$9 price target only takes into account SPMS and not all of the other indications, including Alzheimer’s, MSA, ALS, traumatic brain injury etc.
The only slight annoyance is that I think he mentioned late Q3 / early Q4 for the phase 2a data. But at least we can be certain that we are getting it this year
Huge opportunity here in my opinion
$XBI $LABU
